A Study to Assess the Efficacy and Safety of Weekly Doses of GLM101 in Participants With PMM2-CDG | MicrobiomeTrials← Back to trialsNCT06892288
A Study to Assess the Efficacy and Safety of Weekly Doses of GLM101 in Participants With PMM2-CDG
RecruitingPHASE2, PHASE3INTERVENTIONAL
Trial Details
Start: 2025-07-09Est. Completion: 2026-09-30
Enrollment target: 50 participants Locations- University of Minnesota, Minneapolis, Minnesota, United States
- Icahn School of Medicine at Mount Sinai, New York, New York, United States
- The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
- Seattle Children's Hospital, Seattle, Washington, United States
- UZ Leuven, Campus Gasthuisberg, Leuven, Belgium
- Vseobecna fakultni nemocnice v Praze, Prague, Czechia
- AP-HP Hopital Necker-Enfants Malades, Paris, France
- Universitaetsklinikum Muenster, Münster, Germany
- Azienda Ospedaliero Universitaria Policlinico G. Rodolico-San Marco, Catania, Italy
- Azienda Ospedaliero Universitaria Pisana, Pisa, Italy
- Instytut Matki i Dziecka, Warsaw, Poland
- Unidade Local de Saúde de Santo António, Porto, Portugal
- Hospital Sant Joan de Déu, Esplugues de Llobregat, Spain
- Hospital Universitario 12 de Octubre, Madrid, Spain
- Birmingham Women's and Children's NHS Foundation Trust, Birmingham, United Kingdom
Other microbiome trials you might be interested in
Pmm2-CDGPhosphomannomutase 2 Deficiency
The goal of this clinical trial is to provide continued access to GLM101 to treat PMM2-CDG in people who have previously…
Minneapolis, United StatesCompleted Sep 2029
Phosphomannomutase 2 Deficiency
Clinical and Basic Investigations into Phosphomannomutase deficiency (PMM2-CDG)
This is a natural history (observationa…
Rochester, United StatesCompleted Apr 9, 2026